1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Prestige Brings In New Management As It Consolidates CDMO Control

Prestige Biologics Gets New CEO As Prestige Biopharma Becomes Largest Shareholder

 
• By Dave Wallace

Prestige Biopharma says it is acting to “consolidate group competitiveness” by taking an increased share in Prestige Biologics, at the same time as a new CEO was appointed for the CDMO.

Percentage increase neon sign hand grab
Prestige Biopharma has grabbed a larger stake in Prestige Biologics • Source: Shutterstock

Prestige Biopharma has taken an increased and controlling stake in its Prestige Biologics contract development and manufacturing organization, at the same time as announcing that Duk-Hoon Hyun had been appointed as the unit’s new CEO.

Commenting on the increased shareholding in Prestige Biologics, Prestige Biopharma indicated that it would “become the largest shareholder of Prestige Biologics by acquiring new shares to secure a total of 24.88% of the CDMO company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Business